Wellesley Therapeutics Inc. is a Canadian pharmaceutical research & development company focused on the application of glycobiology to human health and disease. Founded by Dr. Willem Wassenaar in 2003, Wellesley’s N-acetylglucosamine has become one of the leading glucosamine brands in the market. Our mission is to maximize the utility of well-known medicinal substances. When a new product first comes on the market it has usually only been used in one or two clinical conditions and a very limited number of subjects. Over time as more and more patients use the drug in an ever-widening set of clinical circumstances; new insights emerge, as do new uses. Our mission is to search out well-known medicinal substances that continue to show clinical utility. Sometimes this utility will be for a select subset of patients with a given diagnosis and other times it will be in the medication's format or method of administration. Based out of North York, Ontario, Wellesley Therapeutics Inc. seeks to bring to the attention of patients and healthcare professionals information and products that will help them use well-known substances with greater knowledge and skill.